OGN (Organon) Enterprise Value: $10,993 Mil (As of Jun. 25, 2026) ***


OGN Organon & Co OGN
73 GF Score
Price $13.48
GF Value $14.55
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Organon Enterprise Value?

Organon OGN +0.22% 73 Enterprise Value is $10,993 Mil as of Jun. 25, 2026. GuruFocus rates OGN with a GF Score™ of 73/100 and a GF Value™ of $14.55 (Fairly Valued). The stock has 9 warning signs investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Organon's Enterprise Value is $10,993 Mil. Organon's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $1,028 Mil. Therefore, Organon's EV-to-EBIT ratio for today is 10.69.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Organon's Enterprise Value is $10,993 Mil. Organon's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1,391 Mil. Therefore, Organon's EV-to-EBITDA ratio for today is 7.90.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Organon's Enterprise Value is $10,993 Mil. Organon's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $6,163 Mil. Therefore, Organon's EV-to-Revenue ratio for today is 1.78.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Organon's Enterprise Value is $10,993 Mil. Organon's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $850 Mil. Therefore, Organon's EV-to-OCF ratio for today is 12.93.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Organon's Enterprise Value is $10,993 Mil. Organon's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $584 Mil. Therefore, Organon's EV-to-FCF ratio for today is 18.82.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Organon  (NYSE:OGN) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Organon's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10992.976/1028
=10.69

Organon's current Enterprise Value is $10,993 Mil.
Organon's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,028 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Organon's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=10992.976/1391
=7.90

Organon's current Enterprise Value is $10,993 Mil.
Organon's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,391 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Organon's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=10992.976/6163
=1.78

Organon's current Enterprise Value is $10,993 Mil.
Organon's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6,163 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Organon's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=10992.976/850
=12.93

Organon's current Enterprise Value is $10,993 Mil.
Organon's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $850 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Organon's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10992.976/584
=18.82

Organon's current Enterprise Value is $10,993 Mil.
Organon's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $584 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Organon Enterprise Value Related Terms


Organon Enterprise Value Historical Data

* Premium members only.

The historical data trend for Organon's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organon Enterprise Value Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Enterprise Value
Get a 7-Day Free Trial 16,117.60 15,311.55 11,753.13 12,051.36 9,936.47

Organon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12,249.88 10,813.46 10,932.62 9,936.47 9,026.27

OGN vs AMRN, SCLX, MIRA: Enterprise Value Comparison

For the Drug Manufacturers - General subindustry, Organon's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organon Enterprise Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organon's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Organon's Enterprise Value falls into.


OGN
73GF Score
Organon & Co OGN
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organon Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Organon's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as

Organon's Enterprise Value for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of $10,993 Mil mean?
Organon (OGN) has a Enterprise Value of $10,993 Mil as of Jun. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Organon and its competitors.
Is Organon's Enterprise Value too high?
Organon's current Enterprise Value is $10,993 Mil. Overall, Organon has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Enterprise Value compare to AMRN and SCLX?
Organon's Enterprise Value of $10,993 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Organon and its competitors. Organon's current Enterprise Value is $10,993 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.55, compared to a current price of $13.48 — trading 7.4% below its estimated fair value. The current Enterprise Value is $10,993 Mil. Organon's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Organon (OGN), the current Enterprise Value is $10,993 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organon (OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be undervalued. The current stock price of $13.48 is trading 7.4% below its estimated GF Value™ of $14.55. GuruFocus considers Organon to be Fairly Valued.

Key valuation signals for OGN:

  • Enterprise Value: $10,993 Mil
  • GF Value™: $14.55 vs. price of $13.48 (7.4% below fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
73GF Score

Get the complete analysis for OGN

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.48
Price
$14.55
GF Value